News

Tirzepatide (Mounjaro)

Tirzepatide (Mounjaro®)

North west London is participating in the national rollout of Tirzepatide (Mounjaro®)—a new treatment being introduced in the NHS across England to support people living with obesity and serious related health conditions.

This is a phased national programme, meaning that groups of people will become eligible at different times during the rollout based on clinical criteria. Timings for the rollout are being finalised and will be shared as soon as possible.  It is estimated that around 900 people in north west London will be eligible to receive Tirzepatide in the first group.

These individuals must meet national eligibility criteria:

·         they must be aged 18 or over, have a BMI of 40 or higher (or 37.5 for some ethnic groups), and live with at least four of the NHSE defined obesity-related conditions, including type 2 diabetes, high blood pressure, high cholesterol, cardiovascular disease, or sleep apnoea.

 

Tirzepatide will only be prescribed by the NHS as part of a comprehensive treatment plan developed by a multidisciplinary team. This means that anyone prescribed the drug must also engage with weight management support, including lifestyle changes, behavioural advice, and increased physical activity. The medication works best when combined with long-term support and commitment.

Published on 25th Jun 2025